In pigs with coronary artery disease and metabolic syndrome, oral semaglutide improved heart pumping performance and stimulated growth of new coronary blood vessels in the ischemic heart tissue.
Heart grows its own bypassSemaglutide stimulated coronary collateral vessel growth in ischemic heart tissue, providing the first mechanistic evidence for how GLP-1 drugs improve cardiac outcomes in coronary artery disease
What the researchers found
Sixteen Yorkshire swine with diet-induced metabolic syndrome and surgically induced coronary artery disease were randomized to semaglutide (n=8) or control (n=8) for 5 weeks. Semaglutide-treated animals showed significantly improved left ventricular filling, end diastolic volume, stroke volume, and cardiac index (all p<0.05).
The mechanism was identified as enhanced vascular proliferation in the peri-ischemic myocardium — semaglutide stimulated growth of collateral blood vessels around the blocked coronary artery. Coronary arteriole vasoactivity was also improved, with enhanced vessel relaxation. Molecular analysis revealed pro-angiogenic pathway activation in the ischemic territory, including changes in proteins involved in blood vessel formation. The study provides the first mechanistic evidence that GLP-1 receptor agonism directly improves coronary collateralization in the setting of chronic ischemic cardiomyopathy.
Why it matters
Coronary artery disease is the leading cause of death worldwide. While procedures like stenting and bypass surgery open blocked arteries, many patients have disease too diffuse or vessels too small for intervention. Semaglutide's ability to stimulate the heart to grow its own new blood vessels could provide a pharmaceutical alternative — or complement — to surgical revascularization, especially for the millions of diabetic and obese patients who already qualify for GLP-1 therapy.
How the study worked
Sixteen Yorkshire swine were fed a high-fat diet for 5 weeks to induce metabolic syndrome, then underwent ameroid constrictor placement to create focal coronary artery disease. Animals were randomized to oral semaglutide (n=8, 4 male, 4 female) or no drug (n=8) for 5 weeks. Terminal evaluation included left ventricular pressure-volume catheterization, coronary collateral characterization, mounted coronary arteriole vasoactivity testing, and molecular analysis of ischemic myocardium using immunoblotting, immunofluorescence, and proteomics.
What this study cannot tell us
This was a relatively small animal study (8 per group) with a short treatment duration (5 weeks). The ameroid constrictor model produces gradual coronary occlusion, which differs from the acute plaque rupture events that cause most human heart attacks. Pigs, while physiologically similar to humans, are not identical in coronary anatomy or metabolic response. The high-fat diet metabolic syndrome model may not fully recapitulate long-standing human diabetes. Whether these vascular changes would persist or continue to improve with longer treatment is unknown.
How to read the evidence
This is a well-designed large animal study using a clinically relevant pig model of coronary artery disease with metabolic syndrome. The combination of functional (pressure-volume), anatomical (collateral), and molecular (proteomics) data provides strong mechanistic evidence. However, translation to human patients requires clinical confirmation.
When this study was published
Published in 2026, this is a very current study that addresses one of the most pressing questions in cardiovascular medicine: how do GLP-1 drugs protect the heart? The authors explicitly call for clinical trials of early GLP-1 use at CAD diagnosis.
The bigger picture
This study provides the mechanistic 'missing link' explaining how GLP-1 drugs protect the heart in clinical outcomes trials like SELECT and SOUL. Rather than just improving metabolic parameters, semaglutide appears to directly stimulate the growth of new blood vessels in oxygen-starved heart tissue — a process called therapeutic angiogenesis that drug developers have tried to achieve for decades with limited success. The fact that a metabolic drug accomplishes this as a secondary benefit is remarkable and could reshape how cardiologists think about using GLP-1 drugs in coronary artery disease.
Questions still open
- Could semaglutide be prescribed at the time of coronary artery disease diagnosis to promote collateral vessel growth alongside standard cardiac therapy?
- Does the coronary collateralization effect persist or increase with longer treatment duration beyond 5 weeks?
- Would combining semaglutide with exercise — which also promotes collateral vessel growth — produce synergistic cardiac benefits?
Common questions
How can semaglutide make the heart grow new blood vessels?
Why study this in pigs rather than mice?
Read the original research
Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy.
American journal of physiology. Heart and circulatory physiology, 330(3), H651-H663
Citation
Muir, Kelsey C; Stone, Christopher; Harris, Dwight D; Kanuparthy, Meghamsh; Broadwin, Mark; Hamze, Jad; Feng, Jun; Sellke, Frank W. (2026). Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy.. American journal of physiology. Heart and circulatory physiology, 330(3), H651-H663. https://doi.org/10.1152/ajpheart.00828.2025